Table 1:
Demographic and clinical characteristics of 45,260 patients with HCV by SVR status.
| SVR | No SVR | p-value | |
|---|---|---|---|
| N=41,711 | N=3,549 | ||
| Mean age (SD) | 61.8 | 61.41 | 0.0006 |
| Mean follow-up time, yrs (SD) | 2.01 | 2.07 | 0.0002 |
| Sex | |||
| Female | 1449 (3.47) | 76 (2.14) | <0.0001 |
| Male | 40262 (96.53) | 3473 (97.86) | |
| Race/Ethnicity | |||
| White | 22453 (53.83) | 1886 (53.14) | 0.0001 |
| Black | 15585 (37.36) | 1285 (36.21) | |
| Hispanic | 1745 (4.18) | 210 (5.92) | |
| Others | 911 (2.18) | 80 (2.25) | |
| Missing | 1017 (2.44) | 88 (2.48) | |
| Alcohol Abuse | 22052 (52.87) | 2021 (56.95) | <0.0001 |
| Drug Abuse | 20817 (49.91) | 1889 (53.23) | 0.0002 |
| HIV Co-infection | 1717 (4.12) | 135 (3.80) | 0.39 |
| Hypertension | 30800 (73.84) | 2631 (74.13) | 0.7186 |
| Cirrhosis | 12516 (30.01) | 1438 (40.52) | <0.0001 |
| Cirrhosis Complications | 7137 (17.11) | 981 (27.64) | <0.0001 |
| HBV Co-infection | 1285 (3.08) | 126 (3.55) | 0.13 |
| Pre DAA-High Utilization | 20508 (49.17) | 1915 (53.96) | <0.0001 |
| Post DAA-High Utilization | 19971 (47.88) | 2009 (56.61) | <0.0001 |
| Previous HCV Treatment | |||
| None | 33769 (80.96) | 2841 (80.05) | 0.0005 |
| Interferon + Boceprevir/telaprevir | 1598 (3.83) | 103 (2.90) | |
| Interferon +/− ribavirin | 6344 (15.21) | 605 (17.05) | |
| HCV Genotype | |||
| Genotype 1a | 24097 (57.77) | 2039 (57.45) | 0.72 |
| Genotype 1b | 11371 (27.26) | 697 (19.64) | <0.0001 |
| Genotype 2 | 3664 (8.78) | 418 (11.78) | <0.0001 |
| Genotype 3 | 1901 (4.56) | 404 (11.38) | <0.0001 |
| Genotype 4 | 397 (0.95) | 33 (0.93) | 0.97 |
| Genotype 5,6 | 28 (0.07) | 5 (0.14) | 0.22 |
Abbreviations: HCV, hepatitis C virus; SVR, sustained viral response; SD, standard deviation; HBV, hepatitis B virus; DAA, direct acting antivirals. All Ns prior to exclusion for prevalent outcomes. P-values are based on t-tests for continuous variables and chi-square for categorical variables.